Hepatoprotective Effects of Phloridzin on Hepatic Fibrosis Induced by Carbon Tetrachloride against Oxidative Stress-Triggered Damage and Fibrosis in Rats

Gaigai Deng,a Junzhi Wang,a Qiaoyin Zhang,a Haibo He,*a Fangfang Wu,a Tianyan Feng,a Jigang Zhou,b Kun Zou,a and Masao Hattori+c

aHupei Key Laboratory of Natural Products Research and Development, China Three Gorges University; bTraditional Chinese Medicine Clinical Hospital of China, Three Gorges University; Yichang 443002, P. R. China; and cDivision of Metabolic Engineering, Institute of Natural Medicine, University of Toyama; 2630 Sugitani, Toyama 930–0194, Japan. Received January 17, 2012; accepted April 16, 2012.

The present study was to study the hepatoprotective effects of phloridzin (PHL) on hepatic fibrosis induced by carbon tetrachloride (CCl4) in rats, on the basis of this investigation, the possible mechanism of PHL was elucidated. Male Sprague Dawley (SD) rats were randomly divided into six groups: control, model, PHL-L, PHL-M, PHL-H and colchicine. All rats except control group were intraperitoneally injected with CCl4, and control rats were injected with olive oil, twice a week for eight weeks. At the same time, the rats were orally given homologue drugs once a day, respectively. Hepatoprotective effects of PHL were evaluated by liver weight indexes, biochemical values, total antioxidant capacity and total-superoxide dismutase, histopathological observations, hepatic fibrosis, and the hepatic fibrosis relative gene and protein expressions. PHL significantly improved hepatic function; remarkably decreased serum hyaluronic acid (HA), transforming growth factor-β1 (TGF-β1), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and liver tissues hydroxyproline, malondialdehyde (MDA) levels, increased glutathione peroxidase (GSH-Px), total-antioxidant capacity (T-AOC) and total-superoxide dismutase (T-SOD) contents of liver tissues; Real-time polymerase chain reaction (PCR) and immunohisto-chemical results showed PHL might markedly reverse the up-regulated mRNA and protein expressions of the α-smooth muscle actin (SMA), TGF-β1 and tissue inhibitor of metalloproteinase-1 (TIMP1), up-regulate the matrix metalloproteinase-1 (MMP1) mRNA and protein expressions. Histopathological observations provided supportive evidence for biochemical analyses and the hepatic fibrosis relative gene and protein expressions, and with the dose of PHL increasing, the aforesaid improvement became more and more strong. The studies demonstrated that PHL exerted beneficial hepatoprotective effects on hepatic fibrosis induced by CCl4, mainly enhancing antioxidant capacity of liver organizations, reduce the level of lipid peroxidation induced by CCl4, and protect hepatocyte membranes from damage, and alleviate hepatic fibrosis.

Key words phloridzin; hepatic fibrosis; antioxidative; carbon tetrachloride

Hepatic fibrosis, a leading cause of morbidity and mortality, is among the most prevalent health problems worldwide, and its endstage consequence is hepatic cirrhosis, which is characterized by nodule formation and altered hepatic function.1) However, hepatic fibrosis is also a dynamic and sophisticatedly regulated wound healing response to chronic hepatocellular injury. Accumulating evidence suggests that hepatic fibrosis is a reversible disease, therefore an effective treatment would probably prevent or reverse the hepatic fibrotic process.2) In recent years, considerably clinical and experimental evidences show that oxidative stress caused by an imbalance between the oxidant and antioxidant systems of the body in favor of the oxidants should be a major apoptotic stimulus in the different types of acute and chronic liver injury and hepatic fibrosis.3) Carbon tetrachloride (CCl4) is a xenobiotic used extensively to induce oxidative stress. The rats treated with CCl4 are frequently used to produce an experimental model to study hepatic fibrosis.4) Hepatic fibrosis induced by CCl4 is associated with the exacerbation of lipid peroxidation and the depletion of antioxidant status.5) Accordingly, successful antioxidant interventions, which to date has attracted intensive interests from investigators, offer insights into delaying or preventing occurrence and development of hepatic fibrosis, may be a potential and effective therapeutic strategy for prevention and treatment of hepatic fibrosis.

Phloridzin [PHL, 1-(2-[(β-D-glucopyranosyloxy)-4,6-di-hydroxyphenyl]-3-(4-hydroxyphenyl)-propan-1-one], molecular formula: C22H22O10, molecular weight: 436.4. The chemical structure is shown in Fig. 1, which is a dihydrochalcone glycoside and is mainly distributed in plants of Malus.5) At first, PHL was extracted from apple. In recent years, researchers have found that PHL content of Malus hupehensis and Lithocarpus ithossei is higher than apples,6,7) and proved to be the main bioactive principles, such as antioxidation,8) hypoglycemic effect,9) estrogenic and antiestrogenic activities,10) and abundantly used in medical and cosmetics fields.11,12) Recently, PHL is extensively used for digestive diseases,13) although our previous studies demonstrated that PHL had protective effects on acute liver injury caused by CCl4 in a mouse,14) the underlying mechanisms remain poorly understood especially for antioxidant and fibrosis. The goal of our present study was to further confirm PHL hepatoprotective, and evaluate that whether PHL attenuate oxidative stress and inhibit fibrosis in hepatic fibrosis injury rats induced by CCl4, based on these results, investigate the antioxidative and antifibrotic mechanisms involved.

The authors declare no conflict of interest.

* To whom correspondence should be addressed. e-mail: hjy219@126.com

© 2012 The Pharmaceutical Society of Japan
MATERIALS AND METHODS

Materials The leaves of dried Malus hupehensis were supplied by Hubei Key Laboratory of Natural Products Research and Development, as authenticated by Dr. Kun Zou. The voucher specimens were deposited in Hubei Key Laboratory of Natural Products Research and Development, China Three Gorges University. PHL was isolated from the leaves of Malus hupehensis at a purity of more than 99.0%.

Apparatus Image analysis system (Leica, Germany), PT1020 tissue processor and tissue slicer (Leica, Germany), Suprafuge 22 high speed refrigerated centrifuge (Heraeus instruments, Germany), 752 UV and visible range microspectrophotometer (Shanghai, China), CDF-3220 Quantitative realtime polymerase chain reaction (MJ Research, U.S.A.).

Chemicals Colchicine and CCl₄ (Sigma-Aldrich Co., U.S.A.); aspartate aminotransferase (AST), alanine aminotransferase (ALT), hydroxy-proline (HYP), malondialdehyde (MDA), glutathione peroxidase (GSH-Px), total-antioxygen capacity (T-AOC) and total-superoxide dismutase (T-SOD) kits (Nanjing Jiancheng Bioengineering Institute, China); hyaluronic acid (HA), transforming growth factor-β1 (TGF-β1) enzyme-linked immunosorbent assay (ELISA) kits (R&D systems, Inc., Minneapolis, U.S.A.); the monoclonal anti-α-smooth muscle actin (SMA) antibodies (Boster Biological Technology Co., Ltd., China); Monoclonal anti-matrix metalloproteinase-1 (MMP1), anti-angiogenesis inhibitor of metalloproteinase-1 (TIMP1) and anti-horse-radish peroxidase (HRP)-conjugated rabbit anti-mouse IgG secondary antibodies (Santa Cruz, CA, U.S.A.); The PrimeScript® RT Master Mix Kit (Dalian TaKaRa Biotechnology Co., Ltd., China). The THUNDERBIRD SYBR qPCR Mix kit (Osaka TOYOBO Co., Ltd., Japan). The primer sequences for PCR amplification (Shanghai Sangon Biotech Co., Ltd., China). Other reagents were analytically pure.

Experimental Hepatic Fibrosis Male Wistar rats initially weighting 180–220g were purchased from the Laboratory Animal Institute of Hubei Disease Control Center, China. The rights of experimental animals were ensured quantum sati ad during the experiment. Rats were housed in constant conditions at a temperature of 23±3°C, humidity of 60±5%, and on a 12h light–dark cycles. They were fed ad libitum and conditioned in a non-stressful environment for at least 1 week prior to experiments. Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals of China Three Gorges University, and approved by the ethics committee. The whole laboratory procedure was carried out under the permission and surveillance of the ethics committee. The hepatic fibrosis model was performed according to a previous study.15) Briefly, All rats except control group were intraperitoneally injected with 2 mL 50% CCl₄ which diluted in olive oil, while the control rats were given olive oil instead of 50% CCl₄, twice a day for 8 weeks. Phenobarbital induction was started 14d before the first dose of 50% CCl₄ or olive oil at 350mg/L in drinking water to increase liver sensitivity to CCl₄.

Animal Treatment Schedule Animals were randomly divided into six groups: control; PHL-L (PHL, 20mg/kg/d, orally); PHL-M (PHL, 40mg/kg/d, orally); PHL-H (PHL, 80mg/kg/d, orally) and colchicine (2mg/kg/d, orally), with 10 individuals in one group. Treatment of homologous drug was begun on the same time of model building, and vehicle was given to the control and model groups once a day for 8 weeks, and the experiment was carried out after the 8th week.

Liver Index and Serum Biochemical Analysis After measuring body weight, the rats were anaesthetized with urethane (1.2 g/kg, intraperitoneally (i.p.)), the blood samples from abdominal aorta were drawn into heparinized injectors, and the collected blood samples were centrifuged at 3000rpm at 4°C for 15min. Supernatant sera were transferred to clean EP tubes and stored at –80°C. Serum ALT and AST levels were measured by chemichromatometry according to the directions of the reagent kits. After finishing blood collection, the experimental animals were sacrificed, and livers were removed rapidly, washed with physiological saline and weighed, and then treated as described below.

Hepatic Homogenate Biochemical Analysis Hepatic homogenate were centrifuged at 3000rpm at 4°C for 15min. Supernatant homogenates were transferred to clean EP tubes and stored at –80°C. The MDA, GSH-Px, T-SOD and T-AOC levels in liver tissues were measured by chemichromatometry according to the directions of the reagent kits.

Hepatic HYP Content Analysis The content of hepatic HYP was determined by using the hydroxyproline kit following the protocol provided by the manufacturer.

ELISA Serum HA and TGF-β1 were measured by using a rat HA and TGF-β1 ELISA kits according to the manufacturer’s instructions.

Histopathological Examination Liver tissues obtained from all experimental groups were fixed in 4% phosphate-buffered paraformaldehyde, and embedded in paraffin, sectioned at 4μm, stained with hematoxylin and eosin (H&E) for histopathological examination and with Masson’s trichrome for assessment of fibrosis.56) Sections were observed by using a Leica DM2500 microscope and image Leica analytical microsystems. Each sample was observed at a magnification of 200×. The degree of hepatic fibrosis was expressed as the mean of five fields per section, and determined by a single investigator who was unaware of the experimental groups.

Immunohistochemistry for α-SMA, MMP1 and TIMP1 Immunohistochemistry of α-SMA, MMP1 and TIMP1 were performed as follows: liver tissue sections were deparaffinized and the endogenous peroxidase was blocked with H₂O₂ for 10min. Then the sections were incubated with the monoclonal anti-α-SMA antibody (1:500 dilution), monoclonal anti-MMP1 and TIMP1 antibody (1:400 dilution) at 4°C overnight. All antibodies were diluted in phosphate-buffered saline (PBS) containing bovine serum albumin (BSA), and PBS–1% BSA as negative control. The sections were washed
three times with PBS. Primary antibodies were detected with biotin-labeled anti-mouse immunoglobulin G (IgG). Counterstaining was performed with hematoxylin. At least five random fields of each section were examined at a magnification of 400×, and semi-quantitative evaluations were assessed by a reader who was blinded to the animals’ treatment status using a Photo and Image Autoanalysis System.

Quantitative Real-Time Polymerase Chain Reaction (Real-Time PCR) Analysis Total RNA of the hepatic muscles was extracted using TRIZOL reagent according to the supplier’s instruction. RNA was quantitated by optical density measurement at 260 and 280 nm by using a spectrophotometer, and integrity was confirmed by running 4 μL of RNA on a 1.5% agarose gel. RT (reverse transcription) was performed and integrity was confirmed for total cellular RNA by using Revert Aid TM First-Strand cDNA Synthesis Kit for reverse transcription-polymerase chain reaction (RT-PCR); a total volume of 25 μL reaction mixture containing 4.0 μL of 5× reaction buffer, 1.0 μL Ribonuclease inhibitor (20 U/μL), 2.0 μL deoxyribonucleotide triphosphate (dNTP) (10 mM) were mixed and incubated at 37°C for 5 min. After incubation, 1.0 μL MMLV Reverse Transcriptase (200 U/μL) was added and incubated at 37°C for 10 min, 42°C for 60 min and 70°C for 10 min in a thermocycler (Bio-Rad MJ Mini PCR, U.S.A.). Finally, samples were chilled on ice and incubated with 2 U of RNase for 20 min at 70°C for 5 min and chilled on ice for at least 1 min. Subsequently, 4 μL of 5× reaction buffer, 1.0 μL Ribolock™ ribonuclease inhibitor (20 U/μL) and 2.0 μL deoxyribonucleotide triphosphate (dNTP) (10 mM) were mixed and incubated at 37°C for 5 min. After incubation, 1.0 μL MMLV Reverse Transcriptase (200 U/μL) was added and incubated at 37°C for 10 min, 42°C for 60 min and 70°C for 10 min in a thermocycler (Bio-Rad MJ Mini PCR, U.S.A.). Finally, samples were chilled on ice and incubated with 2 U of RNase for 20 min at 37°C before amplifying the target cDNA. cDNA was quantitated by optical density measurement at 260 and 280 nm by using a spectrophotometer, and integrity was confirmed for total cellular RNA by using Revert Aid TM First-Strand cDNA Synthesis Kit for reverse transcription-polymerase chain reaction (RT-PCR); a total volume of 25 μL reaction mixture containing 4.0 μL of total RNA, 1.0 μL of oligo-(dT)18 (0.5 μg/μL) and 7.0 μL of DEPC-treated water was denatured at 70°C for 5 min and chilled on ice for at least 1 min. Subsequently, 4 μL of 5× reaction buffer, 1.0 μL Ribolock™ ribonuclease inhibitor (20 U/μL) and 2.0 μL deoxyribonucleotide triphosphate (dNTP) (10 mM) were mixed and incubated at 37°C for 5 min. After incubation, 1.0 μL MMLV Reverse Transcriptase (200 U/μL) was added and incubated at 37°C for 10 min, 42°C for 60 min and 70°C for 10 min in a thermocycler (Bio-Rad MJ Mini PCR, U.S.A.). Finally, samples were chilled on ice and incubated with 2 U of RNase for 20 min at 37°C before amplifying the target cDNA. cDNA was quantitated by optical density measurement at 260 and 280 nm; the A260/ A280 relation was calculated to determine cDNA quality.

The PCR primers of α-SMA, MMP-1, TIMP-1, TGF-β1 and β-actin were synthesized by Shanghai Sangon Biotech Co., Ltd., China. The sequences of the primers used in this study were shown in Table 1. PCR was carried out in 20 μL of reaction mixture containing 10 μL of THUNDERBIRD qPCR Mix (Illumina, EC-100-1001, U.S.A.), 0.5 μL of each forward and reverse primer, template cDNA and PCR-grade water up to a final volume of 25 μL in a Bio-Rad iQ5 96-well plate. An initial activation at 95°C for 2 min was followed by an amplification target sequence of 40 cycles of pre-denaturing at 95°C for 60 s, then 95°C for 15 s, 60°C for 15 s and 72°C for 30 s in a thermocycler (CFD-3220 quantitative real-time PCR, U.S.A.). Polymerase chain reaction of β-actin chosen as an internal control was carried out in the same tubes as for the genes.

Statistical Analysis All data were expressed as mean± standard deviation (S.D.). Database was set up with SPSS 13.0 software package (SPSS Inc., Chicago, IL, U.S.A.). Differences among groups were analyzed by one-way analysis of variance (ANOVA). Post hoc testing was performed for inter-group comparisons using the least significant difference test (LSD). Resulting p values less than 0.05 was regarded as statistically significant.

RESULTS

Effects of PHL on Body Weight Gain, Liver Index and Serum AST, ALT Levels In the model group, there were significantly decreased body weight gain compared with control group. PHL-H group body weight gain was markedly increased compared with model group (p<0.01), but the body weight gain of the other groups did not remarkably differ; liver index in model group was significantly increased compared with the control group (p<0.01); after treatment with PHL, there were different degree decrease, especially PHL-H (p<0.05); In the the model group, the levels of AST and ALT were markedly decreased relative to the control group (p<0.01); after treatment with PHL, there were different degree decrease, especially PHL-H (p<0.05); PHL markedly reversed these abnormal changes compared with the model group (p<0.05 and p<0.01, respectively), in the treated groups, the effect of PHL-H group was better (Table 2).

Effects of PHL on HYP Content in Liver Tissue and Serum HA Levels In the model group, HYP content in liver tissue and serum HA level were significantly increased compared with the control group (p<0.01), PHL markedly attenuated all abnormalities of HYP and HA (p<0.05 and p<0.01, respectively).

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward primer (5’–3’)</th>
<th>Reverse primer (5’–3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-SMA</td>
<td>CCGAGATCTCACCACGACTACC</td>
<td>TTCAGACCCACATAGCACAG</td>
</tr>
<tr>
<td>MMP-1</td>
<td>GCTGATACGACACTGATCTG</td>
<td>CAACTTTTCTGAGGCTC</td>
</tr>
<tr>
<td>TIMP-1</td>
<td>GCAACCTCCCCAGCTTGTCAC</td>
<td>AGCGTAGGCTTGTGAAGC</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>ACCGCACAACACGCAATCTAGAC</td>
<td>TGTCCTCACAGTTGACTGAAC</td>
</tr>
<tr>
<td>β-Actin</td>
<td>CTATCGGCAATGAGCGCTTC</td>
<td>TGTTGTCGCACTAGGTTCAG</td>
</tr>
</tbody>
</table>

Table 2. Effects of PHL on Body Weight Gain, Liver Index and Serum AST, ALT Levels in the Experimental Rats

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Body weight gain (g)</th>
<th>Liver index (%)</th>
<th>AST (IU/L)</th>
<th>ALT (IU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>10</td>
<td>93.1±8.5</td>
<td>2.6±0.1</td>
<td>12.32±6.04</td>
<td>12.86±2.35</td>
</tr>
<tr>
<td>Model</td>
<td>6</td>
<td>−3.8±9.3**</td>
<td>3.5±0.2**</td>
<td>49.57±1.52**</td>
<td>44.30±14.97**</td>
</tr>
<tr>
<td>PHL-L</td>
<td>7</td>
<td>1.23±6.9</td>
<td>3.4±0.1</td>
<td>34.76±3.41a</td>
<td>35.77±5.49</td>
</tr>
<tr>
<td>PHL-M</td>
<td>9</td>
<td>−0.44±8.4</td>
<td>3.3±0.1</td>
<td>28.81±1.48a</td>
<td>34.53±6.99</td>
</tr>
<tr>
<td>PHL-H</td>
<td>10</td>
<td>47.2±10.5**</td>
<td>3.0±0.1*</td>
<td>22.63±2.60a</td>
<td>32.25±4.81</td>
</tr>
<tr>
<td>Colchicine</td>
<td>6</td>
<td>−13.1±3.2</td>
<td>3.4±0.1</td>
<td>25.19±1.41a</td>
<td>21.39±6.01**</td>
</tr>
</tbody>
</table>

PHL-L, PHL, 20 mg/kg/d; PHL-M, PHL, 40 mg/kg/d; PHL-H, PHL, 80 mg/kg/d; colchicine, 2 mg/kg/d. Data are shown as the mean±S.D. **p<0.01 compared with control group; *p<0.05, **p<0.01 compared with model group.
respectively) compared with the model group, especially in the PHL-M and PHL-H groups (Table 3).

**Effects of PHL on Antioxidant Assay in Liver Tissues**

Compromised hepatic function is always associated with a state of oxidative stress in liver tissues and serum. Thus, the activities of the redox system were measured in liver tissues. Unusually changed activities of oxidant and antioxidant enzymes and the contents were found in the model group. Relative to the control group, decreased antioxidant activity of liver tissues was found in the reduced activities of GSH-Px (73.5%, \( p<0.01 \)), T-SOD (42.5%, \( p<0.01 \)) and T-AOC (68.2%, \( p<0.01 \)) and increased MDA production (264.7%, \( p<0.01 \)), respectively, in the model rats. PHL markedly attenuated all abnormalities of oxidative stress \( (p<0.01, p<0.01, p<0.01, \text{respectively}) \) compared with the model group, especially in the PHL-M and PHL-H groups (Table 4).

**Effects of PHL on Histopathological Changes and Quantification of Hepatic Fibrosis**

H&E staining and Masson’s trichrome staining showed the presence of hepatic injury and fibrosis, marked fatty degeneration, necrosis, inflammation of hepatocytes, and collagen accumulation in the model group (Figs. 2, 3); From the Fig. 3, we found that the collagen in the model group was significantly increased compared with the control group \( (p<0.01) \); after treatment with PHL, the collagen areas was significantly decreased compared with model group \( (p<0.01, \text{respectively}) \), and there was dose–effect relationship among three PHL treated groups.

**Effect of PHL on Serum TGF-β1 and Its mRNA Levels in Liver Tissue**

In the model group, there were significantly increased serum TGF-β1 and its mRNA level in liver tissue relative to the control group \( (p<0.01, \text{respectively}) \); PHL markedly decreased all abnormalities of TGF-β1 \( (p<0.01, p<0.01, \text{respectively}) \) compared with the model group, especially in the PHL-M and PHL-H groups (Fig. 4).

**Effect of PHL on Hepatic Stellate Cells (HSCs)**

Activated in the Liver Tissue α-SMA was the marker of activated HSCs, whose positive expression was mostly found in the blood vessel wall of the control group. In model group, it was located in both fibrous septa and areas of inflammation. In contrast, treatment with PHL obviously attenuated the number of α-SMA positive cells (Figs. 5C–E). In order to further confirm α-SMA associated with HSCs, the α-SMA mRNA and protein expression levels were detected by quantitative real-time PCR and immunohistochemistry. In the model group, the α-SMA mRNA and protein levels were significantly increased compared with control group \( (p<0.01, \text{respectively}) \); After treated with PHL, these up-regulated tendencies of the α-SMA mRNA and protein expressions were remarkably reversed compared with model group \( (p<0.05 \text{and } p<0.01, \text{respectively}) \), and with the dose of PHL progressively increasing, all of these changes became much stronger (Figs. 5G, H). The present results of the quantitative real-time PCR and immunohistochemistry studies provided effectively supportive evidence for the frontal histopathological changes and quantification of hepatic fibrosis analyses.

**Effect of PHL on MMP1, TIMP1 mRNA and Protein Expressions in Liver Tissue**

In the control group, basal mRNA and protein expressions of MMP1 and TIMP1 were low. After induced by CCl₄, the expression levels of MMP1 and TIMP1 appeared increased in different extent compared with control group \( (p<0.01, \text{respectively}) \), especially of TIMP1; In contrast, treatment with PHL further increased the expression levels of MMP1, and significantly decreased TIMP1 expression levels \( (p<0.01, \text{respectively}) \), and the effect of PHL was stronger than colchicine (Figs. 6, 7).

**DISCUSSION**

In the present study, we demonstrated that PHL had beneficial effects on liver function in hepatic fibrosis model rats. These effects were in line with the improvements in decreasing collagen areas and hepatic fibrosis, suppressing oxidative stress-triggered damage, reverse the up-regulated mRNA and protein expressions of the α-SMA, TGF-β1 and TIMP1, up-regulate the MMP1 mRNA and protein expressions, and the meiorative effects of PHL presented in a dose-dependent manner. Hepatoprotective effects of PHL might result from scavenging oxidative stress- triggered damage and fibrosis. These results further confirmed the correlation among oxidative stress, hepatic injury and liver function as well as the recovery in dysfunction by suppressing oxidative stress and hepatic injury.

Hepatic fibrosis is thought to be a reversible disease; however, there is no satisfactory method in clinical

---

### Table 3. Effects of PHL on HYP Content in Liver Tissue and Serum HA Level of the Experimental Rats

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>HYP (μg/g)</th>
<th>HA (ng/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>10</td>
<td>247±46</td>
<td>30.34±5.47</td>
</tr>
<tr>
<td>Model</td>
<td>6</td>
<td>663±96**</td>
<td>59.18±4.18**</td>
</tr>
<tr>
<td>PHL-L</td>
<td>7</td>
<td>547±64</td>
<td>54.7±4.3</td>
</tr>
<tr>
<td>PHL-M</td>
<td>9</td>
<td>304±67##</td>
<td>43.06±8.10##</td>
</tr>
<tr>
<td>PHL-H</td>
<td>10</td>
<td>265±47##</td>
<td>46.68±6.37##</td>
</tr>
<tr>
<td>Colchicine</td>
<td>6</td>
<td>517±105</td>
<td>41.60±7.33##</td>
</tr>
</tbody>
</table>

P/H-L, PHL, 20mg/kg/d; PHL-M, PHL, 40mg/kg/d; PHL-H, PHL, 80mg/kg/d; colchicine, 2mg/kg/d. Data are shown as the mean±S.D. ** \( p<0.01 \) compared with control group; ## \( p<0.01 \) compared with model group.

### Table 4. Effects of PHL on Antioxidant Assay in the Liver Tissues of the Experimental Rats

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>MDA (nmol/mg prot)</th>
<th>GSH-Px (U/mg prot)</th>
<th>T-SOD (U/mg prot)</th>
<th>T-AOC (U/mg prot)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>10</td>
<td>0.68±0.19</td>
<td>16.35±3.25</td>
<td>364.10±44.68</td>
<td>1.32±0.14</td>
</tr>
<tr>
<td>Model</td>
<td>6</td>
<td>2.48±0.52**</td>
<td>4.34±2.93**</td>
<td>209.27±38.44**</td>
<td>0.42±0.12**</td>
</tr>
<tr>
<td>PHL-L</td>
<td>7</td>
<td>2.02±0.75</td>
<td>8.69±3.46**</td>
<td>289.83±45.52</td>
<td>0.69±0.24</td>
</tr>
<tr>
<td>PHL-M</td>
<td>9</td>
<td>1.61±0.38**</td>
<td>12.57±2.89##</td>
<td>351.74±19.32**</td>
<td>0.81±0.11##</td>
</tr>
<tr>
<td>PHL-H</td>
<td>10</td>
<td>1.30±0.29**</td>
<td>13.89±2.54##</td>
<td>365.78±88.70##</td>
<td>0.93±0.09##</td>
</tr>
<tr>
<td>Colchicine</td>
<td>6</td>
<td>1.63±0.57*</td>
<td>9.25±3.05##</td>
<td>277.77±50.49</td>
<td>1.04±0.22##</td>
</tr>
</tbody>
</table>

P/H-L, PHL, 20mg/kg/d; PHL-M, PHL, 40mg/kg/d; PHL-H, PHL, 80mg/kg/d; colchicine, 2mg/kg/d. Data are shown as the mean±S.D. ** \( p<0.01 \) compared with control group; * \( p<0.05 \), ## \( p<0.01 \) compared with model group.
practice to reverse the pathological process. In recent years, researchers have found many traditional Chinese drugs had a very good therapeutic effect in preventing fibrogenesis and other causes of chronic liver injury, which helps to develop a more hopeful future in controlling liver fibrosis and fibrosis. PHL is a mainly active monomer isolated from *Malus hupehensis*. Leaves of *Malus hupehensis* have been drunk as tea for 400 years, and are used for protecting liver from injury in Tuja nationality.

CCl₄ is a well-known hepatotoxic chemical. The main cause of liver injury and fibrosis by CCl₄ is free radicals of its metabolites. CCl₄ generates methyltrichloride radicals (CCl₃·), which are highly unstable and immediately react with cell membrane components, which break cell membrane integrity, and result in ALT, AST in cell plasma leak out. Therefore, serum ALT and AST are the most commonly used biochemical
markers of liver injuries. In present study, we found that PHL could significantly decrease the activities of serum ALT and AST compare with the model group, which demonstrated that PHL had a significantly protective effect on liver injuries. Usually, chronic liver injury may lead to development of fibrosis. During these processes, HSCs play a major role. The phenotype of activated HSCs is characterized by \( \alpha \)-SMA expression, which is recognized as being critical in liver fibrogenesis. HYP is an amino acid found almost exclusively in collagens. Determination of HYP in liver tissues is regarded as a good method to quantify fibrosis, and to evaluate the effectiveness of new potentially antifibrotic agents. In the liver, HA is synthesized and secreted by fat-storing cells. Its concentration in normal liver is low, but in fibrotic liver it shows both relative and absolute increases; consequently, serum HA level is regarded as a good mark for quantify fibrosis. Our present study showed that the protein and mRNA expression levels of liver tissue \( \alpha \)-SMA, liver tissue HYP and serum HA significantly increased in the model group. PHL reduced \( \alpha \)-SMA mRNA and protein levels, and reduced liver tissue HYP content and serum HA level. The results demonstrate that PHL had the inhibition effects on hepatic fibrosis.

Increasing evidences show that oxidative stress contribute to the pathogenesis of various acute and chronic liver diseases. Reactive oxygen species (ROS) cause impairment of cellular membrane stability and cell death by lipid peroxidation.
TIMP1, which inhibits Protein and mRNA Expressions in the Experimental Rats

Liver tissue, serum TGF-β1 prolifermes and stimulates the production and deposition of collagen. The activated HSC also express tissue inhibitors of lower levels of the activities of T-SOD, T-AOC and GSH-Px hepatoprotective effects against lipid peroxidation.

Our present study showed that the content of MDA in liver homogenate increased in the model group, and the activities of T-SOD, T-AOC and GSH-Px decreased correspondingly. PHL markedly inhibited the increase of MDA level and up-regulated lower levels of the activities of T-SOD, T-AOC and GSH-Px in different extents. These results indicated that PHL had the hepatoprotective effects against lipid peroxidation.

Kupffer cells which could secrete TGF-β1 are activated by lipid peroxidation products. TGF-β1 inhibits production of the matrix-degrading enzymes, interstitial collagenase, stromelysin and plasmin by inhibiting of urokinase plasminogen activator, while simultaneously up-regulating expression of TIMP1 and plasminogen activator inhibitor. Liver fibrosis, which is characterized by the excess deposition of extracellular matrix components, is usually the ultimate pathological outcome for the majority of chronic liver injuries. Central to the process of liver fibrosis is the activation of the HSC, which proliferates and stimulates the production and degradation of collagen. The activated HSC also express tissue inhibitors of TIMP1, which inhibits the degradation of interstitial collagens by interstitial collagenase such as MMP1. In situations of spontaneous recovery from liver fibrosis, there is a diminotion of TIMP expression and an increase in collagenase activity with consequent degradation of the collagen matrix. Our results showed that TGF-β1 mRNA levels and serum TGF-β1 protein levels in control group were low, while the expression levels of TGF-β1 were converse in the model group. PHL might down-regulated TGF-β1 mRNA expression levels in liver tissue, serum TGF-β1 levels were the same as the change tendency of TGF-β1 mRNA expression; after treatment with PHL, mRNA and protein expression levels of TIMP1 in liver tissue were significantly down-regulated, while MMP1 were significantly up-regulated correspondingly. These findings implied that PHL down-regulated TGF-β1 expression in vivo through antioxidative effect, and this effect perhaps was the main mechanism of inhibition effect on hepatic fibrosis.

In this study, all of the experimental results demonstrated that PHL exerted beneficially hepatoprotective effects on hepatic fibrosis induced by CCl4, mainly enhancing antioxidant capacity of liver organizations, reduce the level of lipid peroxidation induced by CCl4, and protect hepatocyte membranes from damage, and alleviate hepatic fibrosis. PHL was easy to extract, isolate and identify, so it also showed excellent prospects in the development of some new drugs for treating hepatic fibrosis.

CONCLUSION

In this study, all of the experimental results demonstrated that PHL exerted beneficially hepatoprotective effects on hepatic fibrosis induced by CCl4, mainly enhancing antioxidant capacity of liver organizations, reduce the level of lipid peroxidation induced by CCl4, and protect hepatocyte membranes from damage, and alleviate hepatic fibrosis. PHL was easy to extract, isolate and identify, so it also showed excellent prospects in the development of some new drugs for treating hepatic fibrosis.

Acknowledgement This study was supported by industry–university–research cooperation project from Education Department of Hubei (No: CXY2009B007).

REFERENCES

3) Ghatak S, Biswas A, Dhali GK, Chowdhury A, Boyer JL, Santra A.


